Efficacy and safety of combined trastuzumab and paclitaxel therapy as a second-line treatment in women with metastatic Breast Cancer: A ... View Full Text


Ontology type: schema:ScholarlyArticle     


Article Info

DATE

2006-10-01

AUTHORS

Keiko Furukawa, Yoshinori Ito, Shunji Takahashi, Masataka Sawaki, Nobuyuki Mizunuma, Noboru Horikoshi, Fujio Kasumi, Futoshi Akiyama, Goi Sakamoto, Kiyonori Furukawa, Takashi Tajiri, Kiyohiko Hatake

ABSTRACT

BackgroundIn breast cancer, HER-2 overexpression suggests s poor prognosis. Trastuzumab is a humanized monoclonal antibody with specificity to the HER-2 protein. We evaluated the safety and efficacy of combined trastuzumab and paclitaxel therapy in women with metastatic breast cancer.Patients and MethodsCombination chemotherapy was given to patients with HER-2 overexpressing metastatic breast cancer. All patients had previously received one or more chemotherapy treatments. Patients received a loading trastuzumab dose of 4 mg/kg intravenously (i.v.), followed by 2 mg/kg maintenance dose at weekly intervals. A paclitaxel dose of 80 mg/m2 was administered on the same day as the trastuzumab infusion.ResultsA total of 53 patients were examined. Seventy percent received two or more prior chemotherapy treatments for metastatic breast cancer, and 66.0% of patients had two or more metastatic sites. The overall response rate to our approach was 37.7%. Median time to progression was 12.0 months. Grade 3/4 neutropenia was seen in only 11.3% of patients. Peripheral neuropathy occurred in 65.1% of patients after seven treatments, requiring us to change to biweekly paclitaxel administration in 16 patients. Most of them were able to continue the treatment. Other toxicities were mild and tolerable.ConclusionCombined trastuzumab and paclitaxel therapy, administered as second-line or later treatment, produced lasting objective responses and was well tolerated by women with HER-2 overexpressing metastatic breast cancer. A major obstacle to continuing treatment was peripheral neuropathy. However, modifying the interval to every 2 weeks enabled us to continue the treatment. This combination chemotherapy was safely performed in our outpatient clinic. More... »

PAGES

329-333

Identifiers

URI

http://scigraph.springernature.com/pub.10.2325/jbcs.13.329

DOI

http://dx.doi.org/10.2325/jbcs.13.329

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1018275584

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/17146157


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1112", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Oncology and Carcinogenesis", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Antibodies, Monoclonal", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Antibodies, Monoclonal, Humanized", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Antineoplastic Combined Chemotherapy Protocols", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Breast Neoplasms", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Drug Administration Schedule", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Female", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Infusions, Intravenous", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Neutropenia", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Paclitaxel", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Peripheral Nervous System Diseases", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Receptor, ErbB-2", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Retrospective Studies", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Trastuzumab", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Treatment Outcome", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Surgery for Organ Function and Biological Regulation, Nippon Medical School, Graduate School of Medicine, Tokyo", 
          "id": "http://www.grid.ac/institutes/grid.410821.e", 
          "name": [
            "Department of Medical Oncology, Cancer Institute Hospital, Tokyo", 
            "Surgery for Organ Function and Biological Regulation, Nippon Medical School, Graduate School of Medicine, Tokyo"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Furukawa", 
        "givenName": "Keiko", 
        "id": "sg:person.01045003707.92", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01045003707.92"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Medical Oncology, Cancer Institute Hospital, Tokyo", 
          "id": "http://www.grid.ac/institutes/grid.486756.e", 
          "name": [
            "Department of Medical Oncology, Cancer Institute Hospital, Tokyo"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Ito", 
        "givenName": "Yoshinori", 
        "id": "sg:person.013766206262.48", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.013766206262.48"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Medical Oncology, Cancer Institute Hospital, Tokyo", 
          "id": "http://www.grid.ac/institutes/grid.486756.e", 
          "name": [
            "Department of Medical Oncology, Cancer Institute Hospital, Tokyo"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Takahashi", 
        "givenName": "Shunji", 
        "id": "sg:person.011721243162.37", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.011721243162.37"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Second Department of Surgery, Nagoya University School of Medicine, Nagoya", 
          "id": "http://www.grid.ac/institutes/grid.27476.30", 
          "name": [
            "Second Department of Surgery, Nagoya University School of Medicine, Nagoya"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Sawaki", 
        "givenName": "Masataka", 
        "id": "sg:person.01332406364.07", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01332406364.07"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Medical Oncology, Cancer Institute Hospital, Tokyo", 
          "id": "http://www.grid.ac/institutes/grid.486756.e", 
          "name": [
            "Department of Medical Oncology, Cancer Institute Hospital, Tokyo"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Mizunuma", 
        "givenName": "Nobuyuki", 
        "id": "sg:person.01357134113.91", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01357134113.91"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of General Medicine, Juntendo University School of Medicine, Tokyo", 
          "id": "http://www.grid.ac/institutes/grid.258269.2", 
          "name": [
            "Department of Medical Oncology, Cancer Institute Hospital, Tokyo", 
            "Department of General Medicine, Juntendo University School of Medicine, Tokyo"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Horikoshi", 
        "givenName": "Noboru", 
        "id": "sg:person.01217531417.84", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01217531417.84"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Breast Oncology, Juntendo University School of Medicine, Tokyo", 
          "id": "http://www.grid.ac/institutes/grid.258269.2", 
          "name": [
            "Department of Breast Oncology, Cancer Institute Hospital, Tokyo", 
            "Department of Breast Oncology, Juntendo University School of Medicine, Tokyo"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Kasumi", 
        "givenName": "Fujio", 
        "id": "sg:person.0601110265.31", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0601110265.31"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Pathology, Cancer Institute Hospital, Tokyo, Japan", 
          "id": "http://www.grid.ac/institutes/grid.486756.e", 
          "name": [
            "Department of Pathology, Cancer Institute Hospital, Tokyo, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Akiyama", 
        "givenName": "Futoshi", 
        "id": "sg:person.01264606031.44", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01264606031.44"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Pathology, Cancer Institute Hospital, Tokyo, Japan", 
          "id": "http://www.grid.ac/institutes/grid.486756.e", 
          "name": [
            "Department of Pathology, Cancer Institute Hospital, Tokyo, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Sakamoto", 
        "givenName": "Goi", 
        "id": "sg:person.0715336665.82", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0715336665.82"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Surgery for Organ Function and Biological Regulation, Nippon Medical School, Graduate School of Medicine, Tokyo", 
          "id": "http://www.grid.ac/institutes/grid.410821.e", 
          "name": [
            "Surgery for Organ Function and Biological Regulation, Nippon Medical School, Graduate School of Medicine, Tokyo"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Furukawa", 
        "givenName": "Kiyonori", 
        "id": "sg:person.01172414303.40", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01172414303.40"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Surgery for Organ Function and Biological Regulation, Nippon Medical School, Graduate School of Medicine, Tokyo", 
          "id": "http://www.grid.ac/institutes/grid.410821.e", 
          "name": [
            "Surgery for Organ Function and Biological Regulation, Nippon Medical School, Graduate School of Medicine, Tokyo"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Tajiri", 
        "givenName": "Takashi", 
        "id": "sg:person.01357202667.08", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01357202667.08"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Medical Oncology, Cancer Institute Hospital, Tokyo", 
          "id": "http://www.grid.ac/institutes/grid.486756.e", 
          "name": [
            "Department of Medical Oncology, Cancer Institute Hospital, Tokyo"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Hatake", 
        "givenName": "Kiyohiko", 
        "id": "sg:person.01252161657.78", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01252161657.78"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "sg:pub.10.1038/sj.bjc.6601485", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1030449612", 
          "https://doi.org/10.1038/sj.bjc.6601485"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2006-10-01", 
    "datePublishedReg": "2006-10-01", 
    "description": "BackgroundIn breast cancer, HER-2 overexpression suggests s poor prognosis. Trastuzumab is a humanized monoclonal antibody with specificity to the HER-2 protein. We evaluated the safety and efficacy of combined trastuzumab and paclitaxel therapy in women with metastatic breast cancer.Patients and MethodsCombination chemotherapy was given to patients with HER-2 overexpressing metastatic breast cancer. All patients had previously received one or more chemotherapy treatments. Patients received a loading trastuzumab dose of 4 mg/kg intravenously (i.v.), followed by 2 mg/kg maintenance dose at weekly intervals. A paclitaxel dose of 80 mg/m2 was administered on the same day as the trastuzumab infusion.ResultsA total of 53 patients were examined. Seventy percent received two or more prior chemotherapy treatments for metastatic breast cancer, and 66.0% of patients had two or more metastatic sites. The overall response rate to our approach was 37.7%. Median time to progression was 12.0 months. Grade 3/4 neutropenia was seen in only 11.3% of patients. Peripheral neuropathy occurred in 65.1% of patients after seven treatments, requiring us to change to biweekly paclitaxel administration in 16 patients. Most of them were able to continue the treatment. Other toxicities were mild and tolerable.ConclusionCombined trastuzumab and paclitaxel therapy, administered as second-line or later treatment, produced lasting objective responses and was well tolerated by women with HER-2 overexpressing metastatic breast cancer. A major obstacle to continuing treatment was peripheral neuropathy. However, modifying the interval to every 2 weeks enabled us to continue the treatment. This combination chemotherapy was safely performed in our outpatient clinic.", 
    "genre": "article", 
    "id": "sg:pub.10.2325/jbcs.13.329", 
    "isAccessibleForFree": false, 
    "isPartOf": [
      {
        "id": "sg:journal.1021080", 
        "issn": [
          "1340-6868", 
          "1880-4233"
        ], 
        "name": "Breast Cancer", 
        "publisher": "Springer Nature", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "4", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "13"
      }
    ], 
    "keywords": [
      "metastatic breast cancer", 
      "breast cancer", 
      "paclitaxel therapy", 
      "chemotherapy treatment", 
      "more chemotherapy treatments", 
      "prior chemotherapy treatment", 
      "grade 3/4 neutropenia", 
      "second-line treatment", 
      "single institutional experience", 
      "HER-2 overexpression", 
      "overall response rate", 
      "humanized monoclonal antibody", 
      "BackgroundIn breast cancer", 
      "HER-2 protein", 
      "paclitaxel dose", 
      "maintenance dose", 
      "objective response", 
      "peripheral neuropathy", 
      "combination chemotherapy", 
      "metastatic sites", 
      "median time", 
      "paclitaxel administration", 
      "poor prognosis", 
      "outpatient clinic", 
      "trastuzumab infusion", 
      "ResultsA total", 
      "institutional experience", 
      "patients", 
      "response rate", 
      "trastuzumab", 
      "late treatment", 
      "cancer", 
      "monoclonal antibodies", 
      "therapy", 
      "same day", 
      "dose", 
      "women", 
      "treatment", 
      "weekly intervals", 
      "chemotherapy", 
      "efficacy", 
      "safety", 
      "neutropenia", 
      "neuropathy", 
      "prognosis", 
      "infusion", 
      "clinic", 
      "administration", 
      "progression", 
      "major obstacle", 
      "weeks", 
      "antibodies", 
      "months", 
      "interval", 
      "total", 
      "toxicity", 
      "overexpression", 
      "days", 
      "percent", 
      "specificity", 
      "response", 
      "protein", 
      "rate", 
      "m2", 
      "experience", 
      "sites", 
      "time", 
      "obstacles", 
      "approach"
    ], 
    "name": "Efficacy and safety of combined trastuzumab and paclitaxel therapy as a second-line treatment in women with metastatic Breast Cancer: A single institutional experience", 
    "pagination": "329-333", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1018275584"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.2325/jbcs.13.329"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "17146157"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.2325/jbcs.13.329", 
      "https://app.dimensions.ai/details/publication/pub.1018275584"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2022-12-01T06:25", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20221201/entities/gbq_results/article/article_427.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://doi.org/10.2325/jbcs.13.329"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.2325/jbcs.13.329'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.2325/jbcs.13.329'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.2325/jbcs.13.329'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.2325/jbcs.13.329'


 

This table displays all metadata directly associated to this object as RDF triples.

287 TRIPLES      21 PREDICATES      110 URIs      101 LITERALS      22 BLANK NODES

Subject Predicate Object
1 sg:pub.10.2325/jbcs.13.329 schema:about N0f7896501e4f4ac2aba7ef59822900bb
2 N1da8c1107c3a4be9927ae108a54033e0
3 N215abb65f2f34f6a9ddf2ef324749b2e
4 N2bc5602e2a784872b6838c2646883b07
5 N33611e2284f24072ae8686427ff730f6
6 N3d30d02cbcfa4ccc8e3f71791005aa3f
7 N5f657e21f0e147418e9e67f95c1002a9
8 N70f0327d92514d009ed3966618e5dcd5
9 N85c9d16233db48bd9c3d4bba336bd3aa
10 N881cc0108b66442399d5ff956184c4d5
11 Nbee06541584f40c1aa7d55a5749ad6b9
12 Nd37b0105ef2c4d3d98d4f21ccc261442
13 Nddb1b708456841f1b9f602d9686ec211
14 Ne078f94ab3a340fea65448cd7d95f754
15 Nfd602a7390fa40fb8788b66abb32e121
16 anzsrc-for:11
17 anzsrc-for:1112
18 schema:author N3a7a9d85068e43c28d8097ffefdfa71b
19 schema:citation sg:pub.10.1038/sj.bjc.6601485
20 schema:datePublished 2006-10-01
21 schema:datePublishedReg 2006-10-01
22 schema:description BackgroundIn breast cancer, HER-2 overexpression suggests s poor prognosis. Trastuzumab is a humanized monoclonal antibody with specificity to the HER-2 protein. We evaluated the safety and efficacy of combined trastuzumab and paclitaxel therapy in women with metastatic breast cancer.Patients and MethodsCombination chemotherapy was given to patients with HER-2 overexpressing metastatic breast cancer. All patients had previously received one or more chemotherapy treatments. Patients received a loading trastuzumab dose of 4 mg/kg intravenously (i.v.), followed by 2 mg/kg maintenance dose at weekly intervals. A paclitaxel dose of 80 mg/m2 was administered on the same day as the trastuzumab infusion.ResultsA total of 53 patients were examined. Seventy percent received two or more prior chemotherapy treatments for metastatic breast cancer, and 66.0% of patients had two or more metastatic sites. The overall response rate to our approach was 37.7%. Median time to progression was 12.0 months. Grade 3/4 neutropenia was seen in only 11.3% of patients. Peripheral neuropathy occurred in 65.1% of patients after seven treatments, requiring us to change to biweekly paclitaxel administration in 16 patients. Most of them were able to continue the treatment. Other toxicities were mild and tolerable.ConclusionCombined trastuzumab and paclitaxel therapy, administered as second-line or later treatment, produced lasting objective responses and was well tolerated by women with HER-2 overexpressing metastatic breast cancer. A major obstacle to continuing treatment was peripheral neuropathy. However, modifying the interval to every 2 weeks enabled us to continue the treatment. This combination chemotherapy was safely performed in our outpatient clinic.
23 schema:genre article
24 schema:isAccessibleForFree false
25 schema:isPartOf N09dcd299b8a14b20aed06ebddcfd5555
26 N542ca65b6bf04ad6a480d3d23dcc70f1
27 sg:journal.1021080
28 schema:keywords BackgroundIn breast cancer
29 HER-2 overexpression
30 HER-2 protein
31 ResultsA total
32 administration
33 antibodies
34 approach
35 breast cancer
36 cancer
37 chemotherapy
38 chemotherapy treatment
39 clinic
40 combination chemotherapy
41 days
42 dose
43 efficacy
44 experience
45 grade 3/4 neutropenia
46 humanized monoclonal antibody
47 infusion
48 institutional experience
49 interval
50 late treatment
51 m2
52 maintenance dose
53 major obstacle
54 median time
55 metastatic breast cancer
56 metastatic sites
57 monoclonal antibodies
58 months
59 more chemotherapy treatments
60 neuropathy
61 neutropenia
62 objective response
63 obstacles
64 outpatient clinic
65 overall response rate
66 overexpression
67 paclitaxel administration
68 paclitaxel dose
69 paclitaxel therapy
70 patients
71 percent
72 peripheral neuropathy
73 poor prognosis
74 prior chemotherapy treatment
75 prognosis
76 progression
77 protein
78 rate
79 response
80 response rate
81 safety
82 same day
83 second-line treatment
84 single institutional experience
85 sites
86 specificity
87 therapy
88 time
89 total
90 toxicity
91 trastuzumab
92 trastuzumab infusion
93 treatment
94 weekly intervals
95 weeks
96 women
97 schema:name Efficacy and safety of combined trastuzumab and paclitaxel therapy as a second-line treatment in women with metastatic Breast Cancer: A single institutional experience
98 schema:pagination 329-333
99 schema:productId N322c0e5287a948d5984532eec2d3dcc2
100 N6abb5561609a49fc9f33610e80948fab
101 Nec9056962818412da054d649d7976d54
102 schema:sameAs https://app.dimensions.ai/details/publication/pub.1018275584
103 https://doi.org/10.2325/jbcs.13.329
104 schema:sdDatePublished 2022-12-01T06:25
105 schema:sdLicense https://scigraph.springernature.com/explorer/license/
106 schema:sdPublisher N1b176d4ae64f4f9a9880b512aa4b0a00
107 schema:url https://doi.org/10.2325/jbcs.13.329
108 sgo:license sg:explorer/license/
109 sgo:sdDataset articles
110 rdf:type schema:ScholarlyArticle
111 N09dcd299b8a14b20aed06ebddcfd5555 schema:issueNumber 4
112 rdf:type schema:PublicationIssue
113 N0f7896501e4f4ac2aba7ef59822900bb schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
114 schema:name Antibodies, Monoclonal
115 rdf:type schema:DefinedTerm
116 N17eadd0c08de42939810feb59ccc838d rdf:first sg:person.01357134113.91
117 rdf:rest Nd122a972ad174a48a9858e928e3fa214
118 N1b176d4ae64f4f9a9880b512aa4b0a00 schema:name Springer Nature - SN SciGraph project
119 rdf:type schema:Organization
120 N1da8c1107c3a4be9927ae108a54033e0 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
121 schema:name Retrospective Studies
122 rdf:type schema:DefinedTerm
123 N215abb65f2f34f6a9ddf2ef324749b2e schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
124 schema:name Female
125 rdf:type schema:DefinedTerm
126 N2bc5602e2a784872b6838c2646883b07 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
127 schema:name Paclitaxel
128 rdf:type schema:DefinedTerm
129 N322c0e5287a948d5984532eec2d3dcc2 schema:name dimensions_id
130 schema:value pub.1018275584
131 rdf:type schema:PropertyValue
132 N33611e2284f24072ae8686427ff730f6 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
133 schema:name Drug Administration Schedule
134 rdf:type schema:DefinedTerm
135 N3a7a9d85068e43c28d8097ffefdfa71b rdf:first sg:person.01045003707.92
136 rdf:rest Nb7886364458243c5b77a23ee13ba1982
137 N3d30d02cbcfa4ccc8e3f71791005aa3f schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
138 schema:name Infusions, Intravenous
139 rdf:type schema:DefinedTerm
140 N409d45d6f14e420bbce223d2d6198cd0 rdf:first sg:person.01172414303.40
141 rdf:rest N827e15f3976d4a56b52545bbf6aa524b
142 N48581ab55af846b5a05de40589f426e2 rdf:first sg:person.01264606031.44
143 rdf:rest Nad1413f4757f40f49cca082c7aca5082
144 N542ca65b6bf04ad6a480d3d23dcc70f1 schema:volumeNumber 13
145 rdf:type schema:PublicationVolume
146 N5f657e21f0e147418e9e67f95c1002a9 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
147 schema:name Treatment Outcome
148 rdf:type schema:DefinedTerm
149 N6abb5561609a49fc9f33610e80948fab schema:name doi
150 schema:value 10.2325/jbcs.13.329
151 rdf:type schema:PropertyValue
152 N70f0327d92514d009ed3966618e5dcd5 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
153 schema:name Antibodies, Monoclonal, Humanized
154 rdf:type schema:DefinedTerm
155 N7e0777a0f1cf4e13bbecdfff41a67cba rdf:first sg:person.0601110265.31
156 rdf:rest N48581ab55af846b5a05de40589f426e2
157 N827e15f3976d4a56b52545bbf6aa524b rdf:first sg:person.01357202667.08
158 rdf:rest Ne280fe7a57454d7cbe5bc2c52f3d10e7
159 N85c9d16233db48bd9c3d4bba336bd3aa schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
160 schema:name Neutropenia
161 rdf:type schema:DefinedTerm
162 N881cc0108b66442399d5ff956184c4d5 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
163 schema:name Trastuzumab
164 rdf:type schema:DefinedTerm
165 Nad1413f4757f40f49cca082c7aca5082 rdf:first sg:person.0715336665.82
166 rdf:rest N409d45d6f14e420bbce223d2d6198cd0
167 Nafd68a98d5dc410cb4a150e5a1eff2c8 rdf:first sg:person.01332406364.07
168 rdf:rest N17eadd0c08de42939810feb59ccc838d
169 Nb7886364458243c5b77a23ee13ba1982 rdf:first sg:person.013766206262.48
170 rdf:rest Nbbf4cfd5a41d474e8dfe973689f40765
171 Nbbf4cfd5a41d474e8dfe973689f40765 rdf:first sg:person.011721243162.37
172 rdf:rest Nafd68a98d5dc410cb4a150e5a1eff2c8
173 Nbee06541584f40c1aa7d55a5749ad6b9 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
174 schema:name Receptor, ErbB-2
175 rdf:type schema:DefinedTerm
176 Nd122a972ad174a48a9858e928e3fa214 rdf:first sg:person.01217531417.84
177 rdf:rest N7e0777a0f1cf4e13bbecdfff41a67cba
178 Nd37b0105ef2c4d3d98d4f21ccc261442 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
179 schema:name Peripheral Nervous System Diseases
180 rdf:type schema:DefinedTerm
181 Nddb1b708456841f1b9f602d9686ec211 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
182 schema:name Antineoplastic Combined Chemotherapy Protocols
183 rdf:type schema:DefinedTerm
184 Ne078f94ab3a340fea65448cd7d95f754 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
185 schema:name Humans
186 rdf:type schema:DefinedTerm
187 Ne280fe7a57454d7cbe5bc2c52f3d10e7 rdf:first sg:person.01252161657.78
188 rdf:rest rdf:nil
189 Nec9056962818412da054d649d7976d54 schema:name pubmed_id
190 schema:value 17146157
191 rdf:type schema:PropertyValue
192 Nfd602a7390fa40fb8788b66abb32e121 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
193 schema:name Breast Neoplasms
194 rdf:type schema:DefinedTerm
195 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
196 schema:name Medical and Health Sciences
197 rdf:type schema:DefinedTerm
198 anzsrc-for:1112 schema:inDefinedTermSet anzsrc-for:
199 schema:name Oncology and Carcinogenesis
200 rdf:type schema:DefinedTerm
201 sg:journal.1021080 schema:issn 1340-6868
202 1880-4233
203 schema:name Breast Cancer
204 schema:publisher Springer Nature
205 rdf:type schema:Periodical
206 sg:person.01045003707.92 schema:affiliation grid-institutes:grid.410821.e
207 schema:familyName Furukawa
208 schema:givenName Keiko
209 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01045003707.92
210 rdf:type schema:Person
211 sg:person.011721243162.37 schema:affiliation grid-institutes:grid.486756.e
212 schema:familyName Takahashi
213 schema:givenName Shunji
214 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.011721243162.37
215 rdf:type schema:Person
216 sg:person.01172414303.40 schema:affiliation grid-institutes:grid.410821.e
217 schema:familyName Furukawa
218 schema:givenName Kiyonori
219 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01172414303.40
220 rdf:type schema:Person
221 sg:person.01217531417.84 schema:affiliation grid-institutes:grid.258269.2
222 schema:familyName Horikoshi
223 schema:givenName Noboru
224 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01217531417.84
225 rdf:type schema:Person
226 sg:person.01252161657.78 schema:affiliation grid-institutes:grid.486756.e
227 schema:familyName Hatake
228 schema:givenName Kiyohiko
229 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01252161657.78
230 rdf:type schema:Person
231 sg:person.01264606031.44 schema:affiliation grid-institutes:grid.486756.e
232 schema:familyName Akiyama
233 schema:givenName Futoshi
234 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01264606031.44
235 rdf:type schema:Person
236 sg:person.01332406364.07 schema:affiliation grid-institutes:grid.27476.30
237 schema:familyName Sawaki
238 schema:givenName Masataka
239 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01332406364.07
240 rdf:type schema:Person
241 sg:person.01357134113.91 schema:affiliation grid-institutes:grid.486756.e
242 schema:familyName Mizunuma
243 schema:givenName Nobuyuki
244 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01357134113.91
245 rdf:type schema:Person
246 sg:person.01357202667.08 schema:affiliation grid-institutes:grid.410821.e
247 schema:familyName Tajiri
248 schema:givenName Takashi
249 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01357202667.08
250 rdf:type schema:Person
251 sg:person.013766206262.48 schema:affiliation grid-institutes:grid.486756.e
252 schema:familyName Ito
253 schema:givenName Yoshinori
254 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.013766206262.48
255 rdf:type schema:Person
256 sg:person.0601110265.31 schema:affiliation grid-institutes:grid.258269.2
257 schema:familyName Kasumi
258 schema:givenName Fujio
259 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0601110265.31
260 rdf:type schema:Person
261 sg:person.0715336665.82 schema:affiliation grid-institutes:grid.486756.e
262 schema:familyName Sakamoto
263 schema:givenName Goi
264 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0715336665.82
265 rdf:type schema:Person
266 sg:pub.10.1038/sj.bjc.6601485 schema:sameAs https://app.dimensions.ai/details/publication/pub.1030449612
267 https://doi.org/10.1038/sj.bjc.6601485
268 rdf:type schema:CreativeWork
269 grid-institutes:grid.258269.2 schema:alternateName Department of Breast Oncology, Juntendo University School of Medicine, Tokyo
270 Department of General Medicine, Juntendo University School of Medicine, Tokyo
271 schema:name Department of Breast Oncology, Cancer Institute Hospital, Tokyo
272 Department of Breast Oncology, Juntendo University School of Medicine, Tokyo
273 Department of General Medicine, Juntendo University School of Medicine, Tokyo
274 Department of Medical Oncology, Cancer Institute Hospital, Tokyo
275 rdf:type schema:Organization
276 grid-institutes:grid.27476.30 schema:alternateName Second Department of Surgery, Nagoya University School of Medicine, Nagoya
277 schema:name Second Department of Surgery, Nagoya University School of Medicine, Nagoya
278 rdf:type schema:Organization
279 grid-institutes:grid.410821.e schema:alternateName Surgery for Organ Function and Biological Regulation, Nippon Medical School, Graduate School of Medicine, Tokyo
280 schema:name Department of Medical Oncology, Cancer Institute Hospital, Tokyo
281 Surgery for Organ Function and Biological Regulation, Nippon Medical School, Graduate School of Medicine, Tokyo
282 rdf:type schema:Organization
283 grid-institutes:grid.486756.e schema:alternateName Department of Medical Oncology, Cancer Institute Hospital, Tokyo
284 Department of Pathology, Cancer Institute Hospital, Tokyo, Japan
285 schema:name Department of Medical Oncology, Cancer Institute Hospital, Tokyo
286 Department of Pathology, Cancer Institute Hospital, Tokyo, Japan
287 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...